Northwest Biotherapeutics, Inc.
NWBO
$0.26
-$0.0096-3.56%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 62.34% | -35.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 62.34% | -35.29% | |||
| Cost of Revenue | -20.64% | 29.43% | |||
| Gross Profit | 22.50% | -32.41% | |||
| SG&A Expenses | 13.74% | 16.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.57% | 23.57% | |||
| Operating Income | 6.42% | -24.98% | |||
| Income Before Tax | 31.46% | -45.67% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 31.46% | -45.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 31.46% | -45.67% | |||
| EBIT | 6.42% | -24.98% | |||
| EBITDA | 6.56% | -25.81% | |||
| EPS Basic | 33.94% | -40.65% | |||
| Normalized Basic EPS | 41.94% | -58.97% | |||
| EPS Diluted | 33.94% | -9.00% | |||
| Normalized Diluted EPS | 41.94% | -58.97% | |||
| Average Basic Shares Outstanding | 3.97% | 3.89% | |||
| Average Diluted Shares Outstanding | 3.97% | 3.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||